Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as Ozempic and Wegovy), are now drawing increased attention for their potential ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Patients who received preoperative semaglutide had lower postoperative total weight loss at 12 months compared with controls. Median HbA1c levels and diabetes remission at 1 year were similar ...

investigating the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide on the total cardiovascular (CV) events in patients with CV disease (CVD) who are either overweight or ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in ...